Literature DB >> 15501032

Haloperidol: towards further understanding of the structural contributions of its pharmacophoric elements at D2-like receptors.

Donald M N Sikazwe1, Shouming Li, Leroy Mardenborough, Vivian Cody, Brian L Roth, Seth Y Ablordeppey.   

Abstract

An attempt to understand the pharmacophore-relevant position of the alcoholic moiety in haloperidol and the contributions of other pharmacophoric elements led to the re-synthesis of its tropane analogue (compound 2). An analysis of the binding data suggests that haloperidol binds to the DA receptors with the OH group in the axial position and the OH group, while not essential for binding, enhances binding especially at the D2 receptor. It also became clear that shortening the butyrophenone chain not only reduces binding affinity at the DA receptors but eliminates subtype selectivity.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15501032     DOI: 10.1016/j.bmcl.2004.09.046

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  10 in total

1.  Analogues of the dopamine D2 receptor antagonist L741,626: Binding, function, and SAR.

Authors:  Peter Grundt; Sarah Little Jane Husband; Robert R Luedtke; Michelle Taylor; Amy Hauck Newman
Journal:  Bioorg Med Chem Lett       Date:  2006-10-28       Impact factor: 2.823

2.  Multi-receptor drug design: Haloperidol as a scaffold for the design and synthesis of atypical antipsychotic agents.

Authors:  Kwakye Peprah; Xue Y Zhu; Suresh V K Eyunni; Vincent Setola; Bryan L Roth; Seth Y Ablordeppey
Journal:  Bioorg Med Chem       Date:  2011-12-22       Impact factor: 3.641

3.  Structure-activity relationship studies of SYA 013, a homopiperazine analog of haloperidol.

Authors:  Kwakye Peprah; Xue Y Zhu; Suresh V K Eyunni; Jagan R Etukala; Vincent Setola; Bryan L Roth; Seth Y Ablordeppey
Journal:  Bioorg Med Chem       Date:  2012-01-21       Impact factor: 3.641

4.  Development of CNS multi-receptor ligands: Modification of known D2 pharmacophores.

Authors:  Jagan R Etukala; Xue Y Zhu; Suresh V K Eyunni; Edem K Onyameh; Edward Ofori; Barbara A Bricker; Hye J Kang; Xi-Ping Huang; Bryan L Roth; Seth Y Ablordeppey
Journal:  Bioorg Med Chem       Date:  2016-06-04       Impact factor: 3.641

5.  Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one.

Authors:  Seth Y Ablordeppey; Ramazan Altundas; Barbara Bricker; Xue Y Zhu; Eyunni V K Suresh Kumar; Tanise Jackson; Abdul Khan; Bryan L Roth
Journal:  Bioorg Med Chem       Date:  2008-06-20       Impact factor: 3.641

6.  Structure-activity relationships for a novel series of dopamine D2-like receptor ligands based on N-substituted 3-aryl-8-azabicyclo[3.2.1]octan-3-ol.

Authors:  Noel M Paul; Michelle Taylor; Rakesh Kumar; Jeffrey R Deschamps; Robert R Luedtke; Amy Hauck Newman
Journal:  J Med Chem       Date:  2008-09-06       Impact factor: 7.446

7.  Synthesis and evaluation of ligands for D2-like receptors: the role of common pharmacophoric groups.

Authors:  Donald M N Sikazwe; Nancy T Nkansah; Ramazan Altundas; Xue Y Zhu; Bryan L Roth; Vincent Setola; Seth Y Ablordeppey
Journal:  Bioorg Med Chem       Date:  2008-12-31       Impact factor: 3.641

8.  Evaluation of the behavioral and pharmacokinetic profile of SYA013, a homopiperazine analog of haloperidol in rats.

Authors:  Barbara Bricker; Tanise Jackson; Bernard Boateng; Xue Y Zhu; Seth Y Ablordeppey
Journal:  Pharmacol Biochem Behav       Date:  2012-05-12       Impact factor: 3.533

9.  Further evaluation of the tropane analogs of haloperidol.

Authors:  Dinithia Sampson; Barbara Bricker; Xue Y Zhu; Kwakye Peprah; Nazarius S Lamango; Vincent Setola; Bryan L Roth; Seth Y Ablordeppey
Journal:  Bioorg Med Chem Lett       Date:  2014-07-14       Impact factor: 2.823

10.  Evaluation of SYA16263 as a new potential antipsychotic agent without catalepsy.

Authors:  Barbara A Bricker; Kwame Peprah; Hye J Kang; S Y Ablordeppey
Journal:  Pharmacol Biochem Behav       Date:  2019-02-12       Impact factor: 3.533

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.